The DOI matches its Crossref record; 464 of the 467 references it cites were found in a registry or an index.
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Open accessAbstract
Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. These guidelines, which are based on systematic methods to evaluate and classify evidence, provide a foundation for the delivery of quality cardiovascular care. The ACC and AHA sponsor the development and publication of clinical practice guidelines without commercial support, and members volunteer their time to the writing and review efforts. Clinical practice guidelines provide recommendations applicable to patients with or at risk of developing cardiovascular disease (CVD). The focus is on medical practice in the United States, but these guidelines are relevant to patients throughout the world. Although guidelines may be used to inform regulatory or payer decisions, the intent is to improve quality of care and align with patients’ interests. Guidelines are intended to define practices meeting the needs of patients in most, but not all, circumstances, and should not replace clinical judgment. Recommendations for guideline-directed management and therapy, which encompasses clinical evaluation, diagnostic testing, and both pharmacological and procedural treatments, are effective only when followed by both practitioners and patients. Adherence to recommendations can be enhanced by shared decision-making between clinicians and patients, with patient engagement in selecting interventions on the basis of individual values, preferences, and associated conditions and comorbidities. The ACC/AHA Task Force on Clinical Practice Guidelines strives to ensure that the guideline writing committee both contains requisite expertise and is representative of the broader medical community by selecting experts from a broad array of backgrounds, representing different geographic regions, sexes, races, ethnicities, intellectual perspectives/biases, and scopes of clinical practice, and by inviting organizations and professional societies with related interests and expertise to participate as partners or collaborators. The ACC and AHA have rigorous policies and methods to ensure that documents are developed without bias or improper influence. The complete policy on relationships with industry and other entities (RWI) can be found online. Beginning in 2017, numerous modifications to the guidelines have been and continue to be implemented to make guidelines shorter and enhance “user friendliness.” Guidelines are written and presented in a modular knowledge chunk format, in which each chunk includes a table of recommendations, a brief synopsis, recommendation-specific supportive text and, when appropriate, flow diagrams or additional tables. Hyperlinked references are provided for each modular knowledge chunk to facilitate quick access and review. More structured guidelines–including word limits (“targets”) and a web guideline supplement for useful but noncritical tables and figures–are 2 such changes. This Preamble is an abbreviated version, with the detailed version available online. The reader is encouraged to consult the full-text guideline(P-1) for additional guidance and details, since the executive summary contains mainly the recommendations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For example, the recommended LDL-C level for very high-risk patients has been lowered from < 70 to < 55 mg/mL.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [20]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“For secondary prevention in hypertriglyceridemia, second-line options such as statin add-on or statin-intolerant treatments are icosapent ethyl and fenofibrate.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [20]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Icosapent ethyl and fibrate are second-line treatments that should/may be considered in combination with a statin.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [20]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“ESC and AHA/ACC/multi-society guidelines recommend fibrates for patients with dyslipidaemia with elevated triglycerides despite statin treatment.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [20]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For hypertriglyceridemia (Fig. 3), both guidelines recommend a risk-stratified treatment with statins, icosapent ethyl and/or fibrates.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [20]
Experimental — accuracy not yet measured
21 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet
Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1200303 · Cited by 4,257
RetractedEstruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1806491 · Cited by 1,008
RetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Self-citationAhmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
The Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citation
Research works printed but not linked: 110
- 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
- 10.1016/j.jacl.2012.04.081 · DOI
- 10.1016/s0140-6736(10)61350-5 · DOI · Paper page
- 10.1016/j.jacc.2014.02.615 · DOI · Paper page
- 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
- MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23–33.
- 10.1016/s0140-6736(10)61350-5 · DOI · Paper page
- 10.1056/nejmoa1410489 · DOI · Paper page
- 10.1056/nejmoa1615664 · DOI · Paper page
- 10.1056/nejmoa1410489 · DOI · Paper page
- 10.1056/nejmoa061894 · DOI · Paper page
- 10.1016/s0140-6736(10)61350-5 · DOI · Paper page
- 10.1016/s0140-6736(16)31357-5 · DOI · Paper page
- 10.1056/nejm199610033351401 · DOI · Paper page
- 10.1056/nejm199811053391902 · DOI · Paper page
- 10.1056/nejmoa1410489 · DOI · Paper page
- 10.1056/nejmoa1701131 · DOI · Paper page
- 10.1056/nejmoa1615664 · DOI · Paper page
- 10.1161/cir.0000000000000626 · DOI
- 10.1056/nejm199811053391902 · DOI · Paper page
- 10.1056/nejm199511163332001 · DOI · Paper page
- 10.1016/s0140-6736(10)61350-5 · DOI · Paper page
- 10.1056/nejmoa1410489 · DOI · Paper page
- 10.1001/jama.2016.13985 · DOI · Paper page
- Kastelein, JJ, Ginsberg, HN, Langslet, G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996–3003.
- 10.1016/j.jacc.2016.11.070 · DOI · Paper page
- 10.2337/dc05-2415 · DOI · Paper page
- 10.1001/jama.2014.2630 · DOI · Paper page
- 10.1016/s0140-6736(10)61350-5 · DOI · Paper page
- 10.1056/nejmoa0807646 · DOI · Paper page
- 10.1056/nejmoa1410489 · DOI · Paper page
- 10.1001/jama.2016.13985 · DOI · Paper page
- 10.1056/nejmoa1410489 · DOI · Paper page
- 10.1016/j.jacc.2016.03.519 · DOI · Paper page
- 10.1001/jama.2014.2630 · DOI · Paper page
- 10.1161/01.cir.0000437740.48606.d1 · DOI · Paper page
- 10.1161/01.cir.0000437739.71477.ee · DOI · Paper page
- 10.1056/nejmoa1200303 · DOI · Paper page
- 10.1161/01.atv.0000238352.25222.5e · DOI · Paper page
- 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
- 10.1001/jama.2014.2630 · DOI · Paper page
- 10.1161/circulationaha.108.816694 · DOI · Paper page
- 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
- 10.1056/nejmoa1600176 · DOI · Paper page
- 10.1016/j.jacc.2015.07.066 · DOI · Paper page
- 10.1001/jamacardio.2016.5493 · DOI · Paper page
- 10.1093/eurheartj/ehy217 · DOI · Paper page
- 10.1016/s0140-6736(10)61350-5 · DOI · Paper page
- 10.1016/s0140-6736(11)60739-3 · DOI · Paper page
- Chou R Dana T Blazina I et al. Statin use for the prevention of cardiovascular disease in adults: a systematic review for the US Preventive Services Task Force.. Rockville MD: US Agency for Healthcare Research and Quality 2016. Report No.: 14-05206-EF-2.
- 10.1001/jama.279.20.1615 · DOI · Paper page
- 10.1056/nejmoa0807646 · DOI · Paper page
- 10.1056/nejmoa1600176 · DOI · Paper page
- 10.1001/jama.2016.13985 · DOI · Paper page
- 10.1016/j.jacc.2014.06.1186 · DOI · Paper page
- 10.1001/jama.2014.2630 · DOI · Paper page
- 10.1016/j.jacc.2016.05.084 · DOI
- 10.1016/j.jacc.2015.07.066 · DOI · Paper page
- 10.1161/circoutcomes.110.959247 · DOI · Paper page
- 10.1093/eurheartj/ehy217 · DOI · Paper page
- 10.1016/s0140-6736(06)69472-5 · DOI · Paper page
- 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
- 10.1001/jamacardio.2016.4494 · DOI
- 10.1161/01.cir.0000437741.48606.98 · DOI · Paper page
- 10.1016/j.amjcard.2014.07.043 · DOI
- 10.1001/jamacardio.2016.5493 · DOI · Paper page
- 10.3349/ymj.2017.58.1.82 · DOI
- 10.1016/s0735-1097(17)35217-8 · DOI
- 10.1016/j.jcmg.2016.03.022 · DOI
- 10.1001/jama.2015.7515 · DOI
- 10.1161/circulationaha.115.016846 · DOI
- 10.1016/j.ahj.2009.08.007 · DOI · Paper page
- 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
- 10.1056/nejmoa0807646 · DOI · Paper page
- 10.1161/circulationaha.117.028271 · DOI
- 10.1056/nejmoa1600176 · DOI · Paper page
- 10.1016/s0140-6736(12)60367-5 · DOI · Paper page
- 10.1016/j.jcmg.2016.03.022 · DOI
- 10.1016/j.jacc.2016.05.084 · DOI
- 10.1007/s11096-015-0147-7 · DOI
- 10.1001/jamacardio.2017.2543 · DOI
- 10.1001/jamacardio.2016.5493 · DOI · Paper page
- 10.1161/circulationaha.116.022335 · DOI · Paper page
- 10.1016/j.jacc.2014.01.060 · DOI · Paper page
- 10.1001/jamacardio.2016.4494 · DOI
- 10.1161/01.cir.0000437741.48606.98 · DOI · Paper page
- 10.1001/jama.2014.2630 · DOI · Paper page
- 10.1016/j.jacc.2016.02.055 · DOI · Paper page
- Alluri, K, McEvoy, JW, Dardari, ZA, et al. Distribution and burden of newly detected coronary artery calcium: results from the Multi-Ethnic Study of Atherosclerosis. J Cardiovasc Comput Tomogr. 2015;9:337–344.e1. · DOI
- 10.1016/s0140-6736(06)69472-5 · DOI · Paper page
- Kimura, T, Inoue, T, Taguchi, I, et al. Does high-intensity pitavastatin therapy further improve clinical outcomes? The REAL-CAD study in 13 054 patients with stable coronary artery disease. Circulation 2017:136;e450.
- 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
- 10.1016/s0140-6736(12)60367-5 · DOI · Paper page
- 10.1016/s2213-8587(16)30156-5 · DOI · Paper page
- 10.1016/s0140-6736(11)60739-3 · DOI · Paper page
- 10.1001/jamacardio.2016.4494 · DOI
- 10.1002/14651858.cd009217.pub2 · DOI · Paper page
- 10.1016/j.jacc.2015.01.043 · DOI
- 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
- 10.1016/j.jacc.2016.03.519 · DOI · Paper page
- 10.1016/s0140-6736(10)61350-5 · DOI · Paper page
- 10.1016/s0140-6736(16)31357-5 · DOI · Paper page
- 10.1056/nejmoa1600176 · DOI · Paper page
- 10.1161/01.cir.0000437741.48606.98 · DOI · Paper page
- 10.1056/nejmoa1615664 · DOI · Paper page
- 10.1016/j.jacc.2017.10.001 · DOI
- 10.1016/j.jacc.2016.09.928 · DOI
- 10.1001/jama.2016.11004 · DOI · Paper page
- 10.1002/clc.22535 · DOI
- 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
Cited by
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Self-citationHeart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Self-citationPowers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2019) · Stroke · doi:10.1161/str.0000000000000211 · Cited by 7,468
Metadata
- Authors
- Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., Saseen, J. J., Smith, S. C., Sperling, L., Virani, S. S., & Yeboah, J.
- Affiliations
- ACC/AHA Representative. †AACVPR Representative. ‡ACC/AHA Task Force on Clinical Practice Guidelines Liaison. §Prevention Subcommittee Liaison. ‖PCNA Representative. ¶AAPA Representative. **AGS Representative. ††ADA Representative. ‡‡PM Representative. §§ACPM Representative. ‖‖NLA Representative. ¶¶APhA Representative. ***ASPC Representative. †††ABC Representative.
- ORCID
- Venue
- Circulation
- Published
- 2019-06-18
- Volume
- 139
- Issue
- 25
- Pages
- e1082-e1143
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- PMC
- PMC7403606
- OpenAlex
- W2900034165
- Semantic Scholar
- da6ac7a3ecbbcc23b611a1d39a4c4a999b8a4be4
- Cited by
- 6,185
- References
- 467
- Citations by year
- 2026: 244 · 2025: 582 · 2024: 988 · 2023: 1005 · 2022: 862 · 2021: 1014 · 2020: 891 · 2019: 571
- FWCI
- 796.44
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Touro Scholar (Touro College) (submittedVersion)
- Funders
- National Institute of General Medical Sciences (U54GM115428)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- cardiovascular disease prevention, LDL cholesterol, cardiovascular risk assessment, dyslipidemia, statins, PCSK9 inhibitors, ezetimibe, LDL-C lowering therapy, cardiovascular risk reduction, shared decision-making, guideline adherence, cardiovascular disease risk reduction
- MeSH terms
- Anticholesteremic Agents, Cardiology, Cardiovascular Diseases, Cholesterol, Humans, Hyperlipidemias, Risk Factors, Biomarkers, Treatment Outcome, Risk Assessment, Evidence-Based Medicine, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. https://app.cochat.ai/papers/10.1161/cir.0000000000000625
- The paper
- Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., . . . Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. https://doi.org/10.1161/cir.0000000000000625
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.